These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36322059)

  • 1. Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial.
    O'Brien EC; Mulder H; Jones WS; Hammill BG; Sharlow A; Hernandez AF; Curtis LH
    JAMA Cardiol; 2022 Dec; 7(12):1235-1243. PubMed ID: 36322059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
    Ma Q; Chung H; Shambhu S; Roe M; Cziraky M; Jones WS; Haynes K
    Clin Trials; 2019 Aug; 16(4):419-430. PubMed ID: 31081367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial.
    Marquis-Gravel G; Hammill BG; Mulder H; Roe MT; Robertson HR; Wruck LM; Sharlow A; Harris DF; Pohlman FW; Hernandez AF; Jones WS
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008190. PubMed ID: 34886680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.
    Marquis-Gravel G; Roe MT; Robertson HR; Harrington RA; Pencina MJ; Berdan LG; Hammill BG; Faulkner M; Muñoz D; Fonarow GC; Nallamothu BK; Fintel DJ; Ford DE; Zhou L; Daugherty SE; Nauman E; Kraschnewski J; Ahmad FS; Benziger CP; Haynes K; Merritt JG; Metkus T; Kripalani S; Gupta K; Shah RC; McClay JC; Re RN; Geary C; Lampert BC; Bradley SM; Jain SK; Seifein H; Whittle J; Roger VL; Effron MB; Alvarado G; Goldberg YH; VanWormer JL; Girotra S; Farrehi P; McTigue KM; Rothman R; Hernandez AF; Jones WS
    JAMA Cardiol; 2020 May; 5(5):598-607. PubMed ID: 32186653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
    Sleem A; Effron MB; Stebbins A; Wruck LM; Marquis-Gravel G; Muñoz D; Re RN; Gupta K; Pepine CJ; Jain SK; Girotra S; Whittle J; Benziger CP; Farrehi PM; Knowlton KU; Polonsky TS; Roe MT; Rothman RL; Harrington RA; Jones WS; Hernandez AF
    JAMA Cardiol; 2023 Nov; 8(11):1061-1069. PubMed ID: 37792369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE.
    Ahmad FS; Ricket IM; Hammill BG; Eskenazi L; Robertson HR; Curtis LH; Dobi CD; Girotra S; Haynes K; Kizer JR; Kripalani S; Roe MT; Roumie CL; Waitman R; Jones WS; Weiner MG
    Circ Cardiovasc Qual Outcomes; 2020 Jun; 13(6):e006292. PubMed ID: 32466729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study.
    Shen R; Mulder H; Wruck L; Weissler EH; Robertson HR; Sharlow AG; Kripalani S; Muñoz D; Effron MB; Gupta K; Girotra S; Whittle J; Benziger CP; VanWormer JJ; Polonsky TS; Rothman RL; Harrington RA; Hernandez AF; Jones WS
    J Am Heart Assoc; 2023 Jul; 12(13):e027899. PubMed ID: 37345815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of health plan administrative claims data in participant recruitment for pragmatic clinical trials: An Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) example.
    Shi Q; Shambhu S; Marshall A; Rose-Kennedy E; Robertson H; Paullin M; Jones WS; Cziraky M; Haynes K
    Clin Trials; 2020 Apr; 17(2):212-222. PubMed ID: 32009464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial.
    Marquis-Gravel G; Robertson H; Jones WS; Riley D; Ford DE; Crenshaw D; Joosten YA; Rudov L; Hernandez AF; Hess R
    Trials; 2021 Jan; 22(1):90. PubMed ID: 33494785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study.
    Guimarães PO; Krishnamoorthy A; Kaltenbach LA; Anstrom KJ; Effron MB; Mark DB; McCollam PL; Davidson-Ray L; Peterson ED; Wang TY
    JAMA Cardiol; 2017 Jul; 2(7):750-757. PubMed ID: 28538984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.
    Weissler EH; Stebbins A; Wruck L; Muñoz D; Gupta K; Girotra S; Whittle J; Benziger CP; Polonsky TS; Bradley SM; Hammill BG; Merritt JG; Zemon DN; Hernandez AF; Jones WS
    Vasc Med; 2023 Apr; 28(2):122-130. PubMed ID: 37025023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
    Gaba P; Bhatt DL; Dagenais GR; Bosch J; Maggioni AP; Widimsky P; Leong D; Fox KAA; Yusuf S; Eikelboom JW;
    JAMA Netw Open; 2022 Nov; 5(11):e2243201. PubMed ID: 36409491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
    Girotra S; Stebbins A; Wruck L; Marquis-Gravel G; Gupta K; Farrehi P; Benziger CP; Effron MB; Whittle J; Muñoz D; Kripalani S; Anderson RD; Jain SK; Polonsky TS; Ahmad FS; Roe MT; Rothman RL; Harrington RA; Hernandez AF; Jones WS
    J Am Heart Assoc; 2023 Oct; 12(20):e030385. PubMed ID: 37830344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health record.
    Chu CD; Lenoir KM; Rai NK; Soman S; Dwyer JP; Rocco MV; Agarwal AK; Beddhu S; Powell JR; Suarez MM; Lash JP; McWilliams A; Whelton PK; Drawz PE; Pajewski NM; Ishani A; Tuot DS
    Contemp Clin Trials; 2023 May; 128():107172. PubMed ID: 37004812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.
    Farrant M; Easton JD; Adelman EE; Cucchiara BL; Barsan WG; Tillman HJ; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Zhao W; Pauls K; Walsh KB; Martí-Fàbregas J; Bernstein RA; Johnston SC
    JAMA Netw Open; 2019 Sep; 2(9):e1910769. PubMed ID: 31490536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
    Jones WS; Mulder H; Wruck LM; Pencina MJ; Kripalani S; Muñoz D; Crenshaw DL; Effron MB; Re RN; Gupta K; Anderson RD; Pepine CJ; Handberg EM; Manning BR; Jain SK; Girotra S; Riley D; DeWalt DA; Whittle J; Goldberg YH; Roger VL; Hess R; Benziger CP; Farrehi P; Zhou L; Ford DE; Haynes K; VanWormer JJ; Knowlton KU; Kraschnewski JL; Polonsky TS; Fintel DJ; Ahmad FS; McClay JC; Campbell JR; Bell DS; Fonarow GC; Bradley SM; Paranjape A; Roe MT; Robertson HR; Curtis LH; Sharlow AG; Berdan LG; Hammill BG; Harris DF; Qualls LG; Marquis-Gravel G; Modrow MF; Marcus GM; Carton TW; Nauman E; Waitman LR; Kho AN; Shenkman EA; McTigue KM; Kaushal R; Masoudi FA; Antman EM; Davidson DR; Edgley K; Merritt JG; Brown LS; Zemon DN; McCormick TE; Alikhaani JD; Gregoire KC; Rothman RL; Harrington RA; Hernandez AF;
    N Engl J Med; 2021 May; 384(21):1981-1990. PubMed ID: 33999548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 May; 5(5):532-539. PubMed ID: 32129795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Cohen DJ; Steg PG; Cannon CP; Apruzzese PK; D'Agostino RB; Massaro JM; Mauri L;
    JAMA Cardiol; 2017 May; 2(5):478-487. PubMed ID: 28297015
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.